期刊文献+

舒芬太尼腰硬膜联合治疗重症癌痛的临床疗效观察 被引量:5

Clinical Effects of Combined Spinal Epidural Sufentanil for Severe Cancer Pain
下载PDF
导出
摘要 目的观察舒芬太尼腰硬膜联合治疗重症癌痛的临床效果。方法选取晚期癌痛患者48例,随机分为观察组和对照组,各24例。观察组给予腰硬膜联合治疗,以舒芬太尼和罗哌卡因先行蛛网膜下隙注射,再行硬膜外镇痛;对照组给予单纯硬膜外镇痛。比较2组患者镇痛效果包括治疗前、用药后30 min、持续性、暴发性VAS评分以及总体满意度。结果 2组患者治疗前、用药后30 min、持续性VAS评分比较差异无统计学意义(P>0.05),观察组暴发性VAS评分明显低于对照组(P<0.05);观察组总体满意度明显高于对照组(P<0.05)。结论舒芬太尼腰硬膜联合治疗重症癌痛可有效降低暴发痛VAS评分,提高患者总体满意度,值得临床推广应用。 Objective To observe the clinical effects of combined spinal epidural sufentanil in the treatment of severe cancer pain. Methods 48 cases of advanced cancer patients were randomly divided into the observation group and the control group,24 cases in each. The observation group were given combined spinal epidural treatment,with sufentanil and ropivacaine first subarachnoid space injection,epidural analgesia; epidural analgesia was given to the control group. The analgesic effects of the 2groups were compared before and after treatment for 30 min,continuous of VAS score and overall satisfaction. Results The 2groups of patients before treatment,after treatment for 30 min,continuous of VAS score,the difference had no statistical significance( P〈0. 05),outbreak VAS score of the observation group was significantly lower than that of the control group( P〈0. 05);overall satisfaction of the observation group was significantly higher than that of the control group( P〈0. 05). Conclusion Sufentanil epidural combination therapy for severe cancer pain can effectively reduce persistent pain and outbreak VAS score,improve overall satisfaction of patients,and it is worthy of clinical application.
作者 刘敏
出处 《实用癌症杂志》 2016年第7期1197-1198,1201,共3页 The Practical Journal of Cancer
关键词 舒芬太尼 腰硬膜 麻醉 重症 癌痛 Sufentanil Lumbar epidural Anesthesia Severe Cancer pain
  • 相关文献

参考文献7

二级参考文献56

  • 1陆烈红,叶家薇.疼痛自我评估尺的临床应用[J].现代康复,1998,2(8):833-833. 被引量:1
  • 2李凌江,郝伟,杨德森,张亚林,吴舸,罗友根,黄俊,张斌,刘解宁,廖巨福.社区人群生活质量研究──Ⅲ生活质量问卷(QOLI)的编制[J].中国心理卫生杂志,1995,9(5):227-231. 被引量:447
  • 3郭瑞宏.开胸手术后应用舒芬太尼与芬太尼自控静脉镇痛的临床观察[J].中国疼痛医学杂志,2006,12(4):221-223. 被引量:34
  • 4Stahl KD, Van BW, Janssen P, et al. Receptor affinity and pharmacological potency of a series of narcotic analgesic anti-diar-rheal and neuroleptic drugs [J]. Eur J Pharmacol, 1977, 46(3): 199-205.
  • 5Roth IA, Brechmann J, Dbeblt L, et al. Persistent endocrinol stress response in patients undergoing cardiac surgery[J]. J Endocrinol Invest, 1998, 114(1): 12-19.
  • 6Leysen JE, Gommeren W, Niemegeers CJE. Sufentanil, a superior ligand for u-opiate receptors:binding properties and regional distribution in rat brain and spinal cord [J]. Eur J pharmacol, 1983, 87(2): 209-225.
  • 7Goldstein A, Naidu A. Multiple opioid receptors: Ligand selectivity profiles and binding site signatures [J]. Mol Pharmacol, 1989, 36(2): 265-272.
  • 8[1]Hwang S,Chang T,Kasimis B.Dynamic cancer pain management outcomes:the relationship between pain severity pain relief,functional interference,satisfaction and global quality of life over time.J Pain Symptom Manage,2002,23:190-200.
  • 9[2]Medhurst SJ,Walker K,Bowes M,et al.A rat model of bone cancer pain.Pain,2002,96:129-140.
  • 10[3]Caraceni A,Weinstein SM.Classification of cancer pain syndromes.Oncology,2001,15:1627-1640.

共引文献264

同被引文献51

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部